Sharma, A., Khanani, A. M., Eichenbaum, D., Boyer, D., Shaer, A., Ortiz, T., … and the Inter BIOS Group. (2026). Aflibercept 2 mg Biosimilar (aflibercept-ayyh, Pavblu): Experience of safety in clinical settings-APEX- safety study. Eye (Lond), 40(6), 751–754. https://doi.org/10.1038/s41433-026-04327-1

Sharma, Ashish, Arshad M. Khanani, David Eichenbaum, David Boyer, Alexander Shaer, Trisha Ortiz, Humza Sulahria, Allyza Flores, Carl Regillo, and and the Inter BIOS Group. “Aflibercept 2 mg Biosimilar (aflibercept-ayyh, Pavblu): Experience of safety in clinical settings-APEX- safety study.” Eye (Lond) 40, no. 6 (April 2026): 751–54. https://doi.org/10.1038/s41433-026-04327-1.

Sharma A, Khanani AM, Eichenbaum D, Boyer D, Shaer A, Ortiz T, et al. Aflibercept 2 mg Biosimilar (aflibercept-ayyh, Pavblu): Experience of safety in clinical settings-APEX- safety study. Eye (Lond). 2026 Apr;40(6):751–4.

Sharma, Ashish, et al. “Aflibercept 2 mg Biosimilar (aflibercept-ayyh, Pavblu): Experience of safety in clinical settings-APEX- safety study.” Eye (Lond), vol. 40, no. 6, Apr. 2026, pp. 751–54. Pubmed, doi:10.1038/s41433-026-04327-1.

Sharma A, Khanani AM, Eichenbaum D, Boyer D, Shaer A, Ortiz T, Sulahria H, Flores A, Regillo C, and the Inter BIOS Group. Aflibercept 2 mg Biosimilar (aflibercept-ayyh, Pavblu): Experience of safety in clinical settings-APEX- safety study. Eye (Lond). 2026 Apr;40(6):751–754.